Spots Global Cancer Trial Database for vascular diseases
Every month we try and update this database with for vascular diseases cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations | NCT03691870 | Arteriovenous M... Unruptured Brai... Ruptured Brain ... | Standard Trans-... Trans-Venous Em... | - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Translational Development of Photon-counting CT Imaging | NCT03878134 | Cancer Inflammatory Di... Vascular Diseas... Metabolic Bone ... | PHOTON COUNTING... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients | NCT01447368 | Kidney Failure Secondary Hyper... Vascular Diseas... | Cinacalcet Surgical total ... | 18 Years - 75 Years | The University of Hong Kong | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations | NCT03691870 | Arteriovenous M... Unruptured Brai... Ruptured Brain ... | Standard Trans-... Trans-Venous Em... | - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA) | NCT06409481 | Cardiovascular ... Cardiac Disease... Vascular Diseas... Cancer | Antineoplastic ... | 18 Years - 100 Years | The First Affiliated Hospital of Xinxiang Medical College | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Treatment of Brain AVMs (TOBAS) Study | NCT02098252 | Unruptured Brai... Ruptured Brain ... Arteriovenous M... AVM BAVM | Neurosurgery Radiation thera... Embolization | 5 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy | NCT04657120 | Pulmonary Embol... Embolism Embolism and Th... Vascular Diseas... Cardiovascular ... Lung Diseases Respiratory Tra... Cancer Diagnosis | YEARS algorithm CTPA | 18 Years - | University Hospital, Brest | |
| Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | NCT00773747 | Multiple Myelom... | Vorinostat bortezomib placebo to vori... | 18 Years - | Merck Sharp & Dohme LLC | |
| Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA) | NCT06409481 | Cardiovascular ... Cardiac Disease... Vascular Diseas... Cancer | Antineoplastic ... | 18 Years - 100 Years | The First Affiliated Hospital of Xinxiang Medical College | |
| Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer | NCT00000479 | Cardiovascular ... Cerebrovascular... Coronary Diseas... Heart Diseases Myocardial Infa... Myocardial Isch... Vascular Diseas... | Aspirin Vitamin E Placebo | 45 Years - | Brigham and Women's Hospital | |
| Hamburg City Health Study - a German Cohort Study | NCT03934957 | Coronary Heart ... Stroke Dementia Cancer Health Care Vascular Diseas... Periodontal Dis... Ocular Diseases Respiratory Dis... Obesity | 45 Years - 74 Years | Universitätsklinikum Hamburg-Eppendorf | ||
| Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside | NCT06020651 | Renal Cell Carc... Bladder Cancer MSI-H Cancer Cancer | Arterial Dopple... | 18 Years - | Institut Mutualiste Montsouris | |
| Pragmatic Randomized Control Trial of Telehealth vs Standard Care in Follow-up of Patients With Chronic Conditions | NCT04142710 | Chronic Disease Diabetes Vascular Diseas... Chronic Lung Di... Cancer Psychiatric Dis... | Telemedicine: t... | 18 Years - | University of Oslo | |
| Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients | NCT01447368 | Kidney Failure Secondary Hyper... Vascular Diseas... | Cinacalcet Surgical total ... | 18 Years - 75 Years | The University of Hong Kong | |
| Resection of the Inferior Vena Cava Due to Tumor Involvement | NCT04154761 | Neoplasms Surgery--Compli... Vascular Diseas... Vein Disease | Resection of in... | 18 Years - 80 Years | Hospital Universitario Infanta Cristina | |
| Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA) | NCT06409481 | Cardiovascular ... Cardiac Disease... Vascular Diseas... Cancer | Antineoplastic ... | 18 Years - 100 Years | The First Affiliated Hospital of Xinxiang Medical College | |
| Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma | NCT00525447 | Multiple Myelom... | SGN-40 lenalidomide dexamethasone | 18 Years - | Seagen Inc. | |
| Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside | NCT06020651 | Renal Cell Carc... Bladder Cancer MSI-H Cancer Cancer | Arterial Dopple... | 18 Years - | Institut Mutualiste Montsouris | |
| Resection of the Inferior Vena Cava Due to Tumor Involvement | NCT04154761 | Neoplasms Surgery--Compli... Vascular Diseas... Vein Disease | Resection of in... | 18 Years - 80 Years | Hospital Universitario Infanta Cristina | |
| Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA) | NCT06409481 | Cardiovascular ... Cardiac Disease... Vascular Diseas... Cancer | Antineoplastic ... | 18 Years - 100 Years | The First Affiliated Hospital of Xinxiang Medical College | |
| Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer | NCT00000479 | Cardiovascular ... Cerebrovascular... Coronary Diseas... Heart Diseases Myocardial Infa... Myocardial Isch... Vascular Diseas... | Aspirin Vitamin E Placebo | 45 Years - | Brigham and Women's Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
